
Shenzhen Xinyue Biotechnology
Pioneering DEL 3.0 technology for efficient small molecule drug discovery and optimization.
Date | Investors | Amount | Round |
---|---|---|---|
investor | €0.0 | round | |
investor investor | €0.0 | round | |
* | N/A | Series A | |
Total Funding | 000k |
NewDEL Biotech is at the forefront of small molecule drug discovery, leveraging its proprietary DEL 3.0 technology platform. This platform integrates DNA encoded library (DEL) technology with artificial intelligence to screen and optimize active compounds, particularly targeting proteins essential for viral replication. The company primarily serves the pharmaceutical and biotechnology sectors, focusing on clients seeking advanced drug discovery solutions. Operating within the competitive landscape of biotech innovation, NewDEL Biotech's business model revolves around research and development, supported by strategic financing rounds. Revenue is generated through partnerships, licensing agreements, and collaborative projects. Recent funding from Bangqin Capital and other investors underscores the market's confidence in their approach. The company's commitment to expanding its R&D capabilities and advancing its project pipelines positions it as a significant player in the field of molecular drug discovery.
Keywords: DEL technology, small molecule, drug discovery, AI integration, pharmaceutical, biotechnology, R&D, financing, compound optimization, viral replication.